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Summary  Valvular  pathology  in  infants  and  children  poses  numerous  challenges  to  the  pae-
diatric cardiac  surgeon.  Without  question,  valvular  repair  is  the  goal  of  intervention  because
restoration  of  valvular  anatomy  and  physiology  using  native  tissue  allows  for  growth  and  a  poten-
tially better  long-term  outcome.  When  reconstruction  fails  or  is  not  feasible,  valve  replacement
becomes  inevitable.  Which  valve  for  which  position  is  controversial.  Homograft  and  biopros-
thetic valves  achieve  superior  haemodynamic  results  initially  but  at  the  cost  of  accelerated
degeneration.  Small  patient  size  and  the  risk  of  thromboembolism  limit  the  usefulness  of
mechanical  valves,  and  somatic  outgrowth  is  an  universal  problem  with  all  available  prosthe-
ses. The  goal  of  this  article  is  to  address  valve  replacement  options  for  all  four  valve  positions
within the  paediatric  population.  We  review  current  literature  and  our  practice  to  support
our preferences.  To  summarize,  a  multitude  of  opinions  and  surgical  experiences  exist.  Today,
the valve  choices  that  seem  without  controversy  are  bioprosthetic  replacement  of  the  tri-
cuspid valve  and  Ross  or  Ross-Konno  procedures  when  necessary  for  the  aortic  valve.  On  the
other hand,  bioprostheses  may  be  implanted  when  annular  pulmonary  diameter  is  adequate;  if
not or  in  case  of  right  ventricular  outﬂow  tract  discontinuity,  it  is  better  to  use  a  pulmonary
homograft  with  the  Ross  procedure.  Otherwise,  a  valved  conduit.  Mitral  valve  replacement
remains  the  most  problematic;  the  mechanical  prosthesis  must  be  placed  in  the  annular  position,
Abbreviations: AV, auriculoventricular; AVR, aortic valve replacement; LVOT, left ventricular outﬂow tract; MV, mechanical valve; MVR,
mitral valve replacement; PA, pulmonary autograft; PH, pulmonary homograft; PVR, pulmonary valve replacement; RVOT, right ventricular
outﬂow tract; TV, tricuspid valve; TVR, tricuspid valve replacement; VR, valve replacement.
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avoiding  oversizing.  Future  advances  with  tissue-engineered  heart  valves  for  all  positions  and
new anticoagulants  may  change  the  landscape  for  valve  replacement  in  the  paediatric  popula-
tion.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Les  valvulopathies  chez  l’enfant  constitue  des  nombreux  déﬁs  au  chirurgien  car-
diaque pédiatrique.  Il  va  sans  dire  que  la  réparation  valvulaire  est  la  technique  de  choix
pour la  restauration  de  l’anatomie  valvulaire  et  la  physiologie  utilisant  les  tissus  originaires
permettant  d’aboutir  à  un  bon  développement  et  à  un  résultat  potentiellement  meilleur  à
long terme.  Quand  la  reconstruction  échoue  ou  n’est  pas  faisable,  le  remplacement  valvulaire
devient inévitable.  Quelle  valve  pour  quelle  position  reste  une  question  assez  controversée.
L’homogreffe  et  les  bioprothèses  aboutissent  à  des  résultats  initialement  supérieurs  de  point
de vue  hémodynamique,  mais  toujours  aux  dépens  d’une  détérioration  accélérée.  La  petite
taille des  patients  et  le  risque  thromboembolique  limite  l’utilité  des  valves  mécaniques  et  la
croissance  de  l’enfant  constitue  un  problème  universel  avec  toutes  les  prothèses  disponibles.
Le but  de  cet  article  est  d’adresser  des  options  de  remplacement  valvulaire  pour  les  quatre
valves chez  l’enfant.  À  la  lumière  de  la  littérature  actuelle  et  notre  pratique,  nous  essaierons
de justiﬁer  nos  préférences.  En  résumé,  une  multitude  d’avis  et  d’expériences  chirurgicales
existent.  Aujourd’hui,  les  choix  de  valves  sans  controverse  sont  le  remplacement  biologique  de
la valve  tricuspide  et  le  Ross  ou  Ross-Konno  si  nécessaire  pour  la  valve  aortique.  En  outre,  la
bioprothèse  pulmonaire  peut  être  implantée  si  la  taille  de  l’anneau  le  permet  ;  sinon  ou  en  cas
de discontinuité  entre  le  ventricule  droit  et  l’artère  pulmonaire,  il  est  recommandé  d’utiliser
l’homogreffe  pulmonaire  en  cas  d’intervention  de  Ross,  ou  un  tube  valvé  en  dehors  du  Ross.
Le remplacement  valvulaire  mitrale  chez  les  enfants  reste  la  plus  grande  problématique  ; la
prothèse mécanique  en  position  annulaire  doit  être  réalisée  en  évitant  de  surdimensionner  la
prothèse. Des  avancées  futures  avec  de  nouveaux  substituts  valvulaires  ou  d’anticoagulants  sont
susceptibles  de  changer  les  données  du  remplacement  valvulaire  dans  la  population  pédiatrique.
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heart  disease,  technical  imprecision,  the  type  of  insertion© 2012  Elsevier  Masson  SAS
ackground
alvular  pathology  in  infants  and  children  poses  numerous
hallenges  to  the  paediatric  cardiac  surgeon.  Without  ques-
ion,  valvular  repair  is  the  goal  of  intervention  because
estoration  of  valvular  anatomy  and  physiology  using  native
issue  allows  for  growth  and  a  potentially  better  long-term
utcome.  When  reconstruction  fails  or  is  not  feasible,  valve
eplacement  (VR)  becomes  inevitable.  Which  valve  for  which
osition  is  controversial.  Homograft  and  bioprosthetic  valves
chieve  superior  haemodynamic  results  initially  but  at  the
ost  of  accelerated  degeneration.  Small  patient  size  and  the
isk  of  thromboembolism  limit  the  usefulness  of  mechanical
alves  (MVs),  and  somatic  outgrowth  is  a  universal  problem
ith  all  available  prostheses.  The  goal  of  this  article  is  to
ddress  VR  options  for  all  four  valve  positions  within  the  pae-
iatric  population.  We  review  current  literature  to  support
ur  preferences.
ortic valve replacement
ortic  valve  disease  is  one  of  the  most  common  congenital
ardiac  defects,  occurring  in  5%  of  all  children  with  heart  dis-
ase.  The  bicuspid  aortic  valve  is  the  second  most  common
athological  valve  entity  in  the  paediatric  patient  popula-
ion  that  requires  VR  in  a  high  percentage  of  patients  over
heir  lifetimes  [1].
a
rs  droits  réservés.
oss procedure
ontroversy  over  prosthetic  type  for  aortic  valve  replace-
ent  (AVR)  has  dropped  dramatically  in  the  past  15  years
ecause  of  the  growth  in  popularity  and  excellent  results
btained  with  the  Ross  procedure  (Fig.  1A  and  B).  Pulmonary
utograft  (PA)  has  become  the  ﬁrst  choice  of  AVR  in  chil-
ren  and  adolescents  in  some  institutes  [2,3]. PA  shows
xcellent  haemodynamic  performance,  superior  longevity
Fig.  2)  [4],  freedom  from  anticoagulation  and  haemol-
sis  and  decreased  susceptibility  to  endocarditis.  PA  is
lso  known  to  have  the  potential  for  growth.  However,
he  Ross  procedure  is  a  technically  demanding  procedure
nd  reoperation  for  bleeding  and  postoperative  conduction
bnormality  is  not  as  rare  as  early  complications.  Free-
om  from  autograft  dysfunction,  including  severe  autograft
nsufﬁciency,  ranges  from  75%  to  100%  depending  upon  the
uration  of  follow-up  [5].  Elkins  et  al.  [6]  reported  free-
om  from  autograft  replacement  of  93%  and  freedom  from
evere  autograft  insufﬁciency  or  valve-related  death  of  90%
t  their  12-year  follow-up.  Autograft  insufﬁciency  is  one
f  the  leading  causes  of  reoperation  with  the  Ross  proce-
ure  and  several  factors  are  implicated  as  risk  factors,  such
s  preoperative  diagnosis  of  aortic  insufﬁciency,  presencend  inherent  disease  of  the  pulmonary  valve.  Elkins  et  al.
eported  a  freedom  from  right  ventricular  outﬂow  tract
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Figure 1. Ross intervention. After harvesting the pulmonary autograft and left and right coronary arteries (A), the left ventricular outﬂow
tract is reconstructed with the pulmonary autograft and reimplantation 
reconstructed with a pulmonary homograft (B). By courtesy of Hodder Edof the coronary arteries, and the right ventricular outﬂow tract is
ucation, London.
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Figure 2. Freedom from reoperation after initial aortic valve
replacement (AVR) stratiﬁed by prosthetic type. A multivariable
equation was constructed for remaining alive after initial AVR
without subsequent valve replacement according to the original
competing-risk model and forcing all valve types into the equation.
The resulting model was then solved for a hypothetical 10-year-old
patient of 40 kg undergoing operation in 1990. The autograft has
superior longevity, whereas the tissue valves and allografts have
considerably worse durability. The numbers in parentheses repre-
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Figure 3. Kaplan-Meier graph depicting freedom from all valve-
related reoperations after homograft or autograft replacement of
the aortic valve. Means ± 67% conﬁdence limits for three time inter-
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4].
RVOT)  homograft  replacement  of  90%  at  12  years  for  chil-
ren.  Rates  of  freedom  from  RVOT  were  also  similar  for
ther  authors  [7].  Because  of  the  diminishing  availability  of
omografts,  several  conduits  are  used  to  reconstruct  RVOT;
owever,  their  durability  seems  to  be  worse  than  that  of
omografts  [5].  Finally,  Elkins  et  al.  [6]  reported  freedom
rom  all  valve-related  morbidity  of  79%  at  11  years.
Husain  et  al.  [8]  reported  that  freedom  from  replacement
f  the  PA  was  96%  at  10  years.  Freedom  from  replacement
f  the  pulmonary  homograft  (PH)  was  96%  at  10  years.
Technical  modiﬁcations,  such  as  resection  and  graft
eplacement  of  a  dilated  ascending  aorta,  annular  rein-
orcement  with  circumferential  felt  or  Dacron  and/or
einforcement  of  the  entire  autograft  root,  are  all  options
o  minimize  autograft  dilation  and  insufﬁciency.
In  neonates  and  infants  with  left  ventricular  outﬂow  tract
LVOT)  obstruction,  the  Ross  procedure,  although  more  com-
lex,  provides  excellent  normalization  of  haemodynamics
nd  regression  of  left  ventricular  hypertrophy  by  avoiding
esidual  lesions  [9].  Despite  the  need  for  reoperation  and
otential  for  autograft  root  dilation,  the  Ross  and  Ross-
onno  procedures  remain  the  best  choice  for  AVR  in  infants
ith  multilevel  LVOT  obstruction  or  severe  aortic  insufﬁ-
iency  following  valvuloplasty  [10].
echanical aortic valve replacement
Vs  are  reserved  for  children  who  have  connective  tissue
isorders  or  whose  native  pulmonary  valves  are  unsuit-
ble  for  translocation  to  the  aortic  position.  AVR  using
echanical  prosthetic  valves  in  children  often  requires
nnular  enlargement  to  insert  commercially  available  pros-
heses  [11]. The  Yamaguchi  [12], Manouguian  [13]  and  Konno
14]  procedures  enable  insertion  of  prostheses  two  sizes
B
a
aals are indicated [19].
igger  than  that  of  in  situ  insertion.  The  Konno  procedure
equires  incision  of  the  ventricular  septum,  which  might
ause  ventricular  dysfunction  or  conduction  abnormality.  In
he  Manouguian  procedure,  the  incision  is  extended  to  the
nterior  mitral  leaﬂet  and  might  cause  mitral  insufﬁciency.
he  Yamaguchi  procedure  does  not  damage  either  the  ven-
ricular  septum  or  the  mitral  leaﬂet.
Shanmugam  et  al.  [11]  reported  that  no  rereplacement
f  prosthesis  was  required  when  the  patient  received  a  pros-
hesis  21  mm  or  larger  in  size.  Masuda  et  al.  [15]  reported
hat  freedom  from  rereplacement  of  aortic  valve  was  94%
t  15  years  and  was  at  least  compatible  with  the  results
f  other  series  with  mechanical  prostheses  by  Shanmugam
t  al.  (92%  at  20  years)  [11]  and  Ruzmetov  et  al.  (84%  at
9  years)  [16], and  was  not  inferior  to  the  results  of  PA
eported  by  Elkins  et  al.  (93%  at  12  years)  [6]  and  Pasquali
t  al.  (81%  at  8  years)  [7].  An  actuarial  survival  rate  of  92%
nd  a  freedom  from  valve-related  complications  rate  of  86%
t  15  years  seem  quite  acceptable  [15]. Regression  of  left
entricular  dilatation  in  children  with  severe  aortic  regurgi-
ation  can  be  observed  on  echocardiography  and  magnetic
esonance  imaging  after  timely  AVR  [17].
Concerning  anticoagulation  problems,  Akhtar  et  al.
18]  reported  a  study  assessing  long-term  survival  and
nticoagulant-related  complications  after  mechanical  VR  in
dolescents  with  rheumatic  heart  disease.  Patient  survival
ates  at  30  days,  3  months  and  1,  5  and  10  years  were  95.5%,
3.2%,  87.5%,  82.9%  and  82.9%,  respectively.  MV  thrombo-
is  occurred  in  4.5%  patients  and  was  fatal  in  3.4%  of  them.
evere  haemorrhage  required  hospital  admission  in  4.5%  of
atients.
Although  quite  durable,  MVs  require  chronic  anticoag-
lation,  which  can  be  poorly  tolerated  and  quite  difﬁcult
o  control  in  some  children.  Patient  growth  and  acquired
atient-prosthesis  mismatch  are  not  uncommon  problems
ith  mechanical  AVR.
ioprostheses, homografts and xenograftsioprostheses,  homografts  and  xenografts  in  children  and
dolescents  have  been  largely  abandoned  due  to  acceler-
ted  degeneration  (Fig.  3)  [19]. In  the  younger  age  group,
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there  is  a  signiﬁcant  risk  of  structural  valve  deterioration,
reported  to  range  from  71%  to  87%  at  10  years  [20].
Decellularized  aortic  valve  allografts  [21]  appeared  to  be
more  resistant  to  calciﬁcation  and  did  not  show  any  major
structural  and  morphological  alteration.  If  these  results  are
conﬁrmed  with  longer  follow-up  periods,  this  technique  may
be  a  promising  alternative  to  AVR  for  a  selected  group  of
patients,  especially  females  [22].
Mortality
Karamlou  et  al.  [4]  identiﬁed  that  younger  age  and  lower
weight  at  initial  AVR  unfavourably  inﬂuenced  mortality  with-
out  repeated  replacement,  especially  in  the  extreme  cases
of  very  young  age  or  very  low  weight.  Previously  published
reports,  which  showed  that  neonates  and  those  aged  less
than  6  months  compose  the  highest-risk  group,  agree  with
these  ﬁndings  [1].  There  are  several  reasons  for  poor  out-
come  in  this  population.  First,  young  age  at  initial  operation
was  signiﬁcantly  associated  with  the  presence  of  other
cardiac  anomalies,  including  important  mitral  valve  dys-
function,  which  accounted  for  substantial  mortality.  Others
have  noted  that  those  with  concomitant  cardiac  lesions
fare  worse  than  those  with  isolated  aortic  valve  disease
[1].  Second,  the  preoperative  clinical  status  of  younger
patients,  especially  neonates,  is  likely  to  be  considerably
worse  than  those  undergoing  later  AVR.  Correlation  between
poor  preoperative  left  ventricular  function  (fractional  short-
ening  <  25%)  and  late  mortality  has  been  established.  Finally,
younger  patients  (and  those  with  lower  weight)  are  at
highest  risk  of  prosthesis  outgrowth  necessitating  subse-
quent  repeated  replacement  or  intervention,  which  may
contribute  to  increased  mortality.  The  need  for  concomitant
aortic  arch  reconstruction  or  augmentation  was  also  identi-
ﬁed  as  an  incremental  risk  factor  for  death  without  a  second
AVR.
In  a  recent  study,  Alsouﬁ  et  al.  [23]  reported  on  346
children  who  underwent  AVR  (215  Ross  procedures;  131
placements  of  a  mechanical  prosthesis).  Patients  undergo-
ing  the  Ross  procedure  were  younger,  more  likely  to  have
a  congenital  cause  and  less  likely  to  have  a  rheumatic  or
connective  tissue  cause;  they  had  a  lower  frequency  of
regurgitation,  required  more  annular  enlargement  and  had
less  concomitant  cardiac  surgery.  Competing-risk  analysis
showed  that  16  years  after  AVR,  20%  of  patients  had  died
without  subsequent  AVR,  25%  had  undergone  a  second  AVR
and  55%  remained  alive  without  further  replacement.  Fac-
tors  associated  with  early-phase  death  included  MV  and
a  non-rheumatic  cause.  MVs  were  also  associated  with
constant-phase  mortality.  Repeated  AVR  was  associated  with
the  Ross  procedure  and  a  rheumatic  cause.  In  children  who
received  a  mechanical  prosthesis,  younger  age  and  smaller
valve  size  were  signiﬁcant  risk  factors  for  death.  Freedom
from  homograft  replacement  after  the  Ross  procedure  was
82%  at  16  years  of  follow-up.  Results  from  this  study  showed
good  outcomes  and  an  acceptable  complication  rate  with
both  valve  choices.  Given  the  signiﬁcantly  increased  risk  of
early  and  late  death  in  younger  children  receiving  smaller
MVs,  the  Ross  procedure  confers  a  survival  advantage  in
this  age  group  at  the  expense  of  increased  reoperation  risk,
especially  in  patients  with  a  rheumatic  cause.
p
i
p
t521
itral valve replacement
ifferent  congenital  malformations  may  affect  the  mitral
alve  either  in  isolation  or  in  association  with  other  car-
iac  anomalies  [24]. Improvements  in  surgical  techniques
ave  made  it  possible  to  obtain  good  results  when  a  mitral
epair  is  required.  Anatomical  analysis  is  of  particular  impor-
ance  for  surgical  management  and  prognosis.  As  a  result,
he  need  for  mitral  valve  replacement  (MVR)  is  relatively
ncommon  in  children.  But  in  some  cases,  MVR  is  the  last
ecourse.  The  most  common  indications  for  MVR  in  children
nclude  rheumatic  disease,  endocarditis,  mitral  stenosis  in
hone’s  syndrome  or  failed  auriculoventricular  (AV)  canal
epair.  MVR  carries  the  highest  mortality  for  any  paediatric
R  and  has  a  much  poorer  long-term  prognosis  than  any
ther  VR  in  children.  The  reported  operative  mortality  for
VR  in  infants  is  5%  to  52%.  The  5-  and  10-year  survival  for
hese  patients  has  been  reported  as  33%  to  95%  (Table  1)
25—36].  Because  of  these  concerning  statistics,  alternatives
o  MVR  should  include  aggressive  attempts  at  valve  repair
nd  sometimes  conversion  from  biventricular  to  single  ven-
ricle  repair  or  even  cardiac  transplantation  [30]. MVR  is
ommon  in  small  children  who  have  a  small  mitral  annu-
us.  Unfortunately,  annular  enlargement  options  are  sparse.
ttempting  to  oversize  the  prosthesis  at  the  time  of  MVR
an  produce  subaortic  obstruction  and  should  be  avoided.
rosthetic  leaﬂet  entrapment  and  conduction  block  after
VR  pose  signiﬁcant  postoperative  morbidity  and  mortality.
ommon  reasons  for  reoperation  include  prosthetic  steno-
is,  thrombosis  and  endocarditis.  In  comparison  with  initial
VR,  the  mitral  annulus  can  usually  be  upsized  2  to  3  mm
n  diameter  at  the  time  of  redo-MVR.  Low-proﬁle  bileaﬂet
yrolytic  carbon  valves  are  the  most  popular  prostheses  for
VR;  however,  all  MVs  require  lifelong  anticoagulation.  Bio-
rosthetic  xenografts  and  mitral  homograft  valves  do  not
equire  anticoagulation  but  have  limited  durability  of  3  to
 years  in  the  mitral  position  [29].
In an  attempt  to  ﬁnd  a  more  durable  tissue  valve  that
oes  not  require  lifelong  anticoagulation,  some  centres  used
he  PA  MVR  or  Ross  II  technique  [8]  in  selected  older  chil-
ren  and  young  adults  whose  pulmonary  valves  are  large
nough  for  MVR  (20  mm  in  diameter).  Ross  II  does  not  require
nticoagulation  and  has  other  potential  advantages,  such  as
roviding  a  ﬂexible  prosthesis,  thus  removing  the  need  for
 rigid  structure  in  the  mitral  annulus.  However,  experience
s  scarce.
urvival
he  largest  review  of  MVR  in  the  young  (<  5  years  of  age)
aediatric  population  was  published  by  Caldarone  et  al.
30], who  analysed  data  gathered  by  the  Pediatric  Cardiac
are  Consortium  (45  centres;  1982—1999).  MVR  was  per-
ormed  176  times  in  139  patients,  all  less  than  5  years  of
ge.  Operative  morbidity  in  these  patients  included  heart
lock  requiring  pacemaker  implantation  (16%),  endocarditis
6%),  thrombosis  (6%)  and  stroke  (2%).  The  diagnosis  of  com-
lete  atrioventricular  septal  defect,  Shone’s  syndrome,  an
ncreased  ratio  of  prosthetic  size/weight  and  supra-annular
osition  were  all  found  to  be  statistically  signiﬁcant  predic-
ors  of  early  mortality.
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Table  1  Literature  review  of  postoperative  mortality  and  long-term  survival  after  mitral  valve  replacement.
Article  Number  of  patients  Postoperative
mortality  (%)
5-year  survival  (%)  10-year  survival  (%)
Younger  Older  Younger  Older  Younger  Older  Younger  Older
Caldarone  et  al.,
2001  [30]
< 5  years
(n  =  139)
18  75  74
Alexiou  et  al.,
2001  [26]
< 5  years
(n  =  23)
5—16  years
(n  =  21)
5  0  61  95
Erez  et  al.,  2003
[31]
< 2  years
(n  =  29)
2—18  years
(n  =  61)
52  3
Vohra  et  al.,  2006
[36]
<  5  years
(n  =  24)
21
Beierlein  et  al.,
2007  [29]
< 2  years
(n  =  21)
2—18  years
(n  =  23)
41 6 33 90 33 81
Ackermann  et  al.,
2007  [25]
< 6  years
(n  =  69)
11  65  65
Selamet  Tierney
et  al.,  2008  [35]
< 5  years
(n  =  118)
75 56
Alsouﬁ  et  al.,  2010
[28]
<  2  years
(n  =  37)
2—8  years
(n  =  42)
30  6
Henaine  et  al.,
2010  [32]
< 5  years
(n  =  29)
13  86  86
Raﬁi  et  al.,  2011
[34]
< 2  years
(n  =  18)
2—18  years
(n  =  27)
11  0  82  85  82  85
Alsouﬁ  et  al.,  2011
[27]
<  2  years
(n  =  36)
2—18  years
(n  =  271)
26  4  70  85  70  85
Kanter  et  al.,  2011 <  4  years 7 87
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Figure 4. Competing-risks depiction of outcomes following mitral
valve replacement (MVR) in children aged 1 to 18 years. The compet-
ing risks for the two events (mitral reoperation and death without
mitral reoperation) showed that at 10 years following MVR, approx-
imately 15% of patients had died and 24% had undergone mitral
reoperation, while at 20 years following MVR, approximately 17% of
p
3
v[33] (n  =  15)
In  our  centre  [32], the  comprehensive  mortality  is  17%.
mong  ﬁve  deceased  children,  two  had  a  complete  AV  canal
nd  one  had  a  partial  AV  canal;  one  child  had  Shone’s  syn-
rome  with  several  previous  operations,  among  them  a  Ross
rocedure  for  the  left  outﬂow  tract  (the  delayed  treatment
esulted  in  a  major  alteration  of  the  function  of  the  left
entricle);  and  the  last  child  had  a  hammock  mitral  valve
ssociated  with  an  aortic  valvular  stenosis.  Therefore,  mor-
ality  is  linked  to  the  complexity  of  associated  cardiopathies
37].
On  the  other  hand,  Raﬁi  et  al.  [34]  found  that  there  was
o  signiﬁcant  difference  in  survival  between  patients  aged
ess  than  2  years  and  patients  aged  2  to  18  years;  age  less
han  2  years  remains  a  risk  factor  for  reoperation  but  not
or  mortality.
Conversely,  Alsouﬁ  et  al.  (Fig.  4)  [27]  in  a  recent  study
f  307  children  who  underwent  MVR,  showed  that  factors
or  mortality  were:  younger  age  (<  3  years)  at  time  of  MVR;
onger  cross-clamp  time;  postoperative  complications  (com-
lete  heart  block,  bleeding  and  low  cardiac  output);  and
igher  prosthesis  size/body  surface  area—predicted  mitral
nnulus  size.  Of  importance,  patients  with  underlying  con-
enital  mitral  valve  disease  had  worse  survival  compared
ith  those  with  other  pathologies,  especially  rheumatic
ever.
Ackerman  et  al.  [25]  found  that  age,  weight,  body
urface  area,  predicted  annulus  diameter,  prior  surgery,
nderlying  disease  and  ratio  of  prosthetic  valve  diame-
er  to  body  weight  were  signiﬁcant  predictors  of  death.
ariables  associated  with  rereplacement  of  the  systemic
a
v
o
oatients had died, 51% had undergone mitral reoperation and only
3% were alive and free from mitral reoperation [27]. MV: mitral
alve.trioventricular  valve  were  body  surface  area,  prosthetic
alve  diameter,  predicted  annulus  diameter  and  presence
f  multiple  left-sided  obstructive  lesions.  The  majority
f  patients  received  a  prosthesis  that  was  larger  than
523
Figure 5. Kaplan-Meier curves depicting freedom from redo
mitral valve replacement (MVR) and placement of a permanent
pacemaker. Dashed lines represent 95% conﬁdence intervals. Free-
dom from pacemaker placement among 2-week survivors was 81%
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RValve  replacement  in  children  
the  predicted  annulus  diameter.  There  was  good  corre-
lation  between  the  prosthetic  valve  diameter  and  the
measured  annulus  diameter.  Mismatch,  as  described  by  the
difference  in  z  scores  of  prosthetic  valve  diameter  and  mea-
sured  annulus  diameter,  was  not  a  signiﬁcant  predictor  of
death  or  rereplacement  of  the  systemic  atrioventricular
valve.
Annular or supra-annular
Supra-annular  MVR  is  useful  for  children  with  a  small  annu-
lus.  Kanter  et  al.  [33]  found  that  operative  survival  was  good
with  infrequent  heart  block.  Complications  are  common,
including  pulmonary  vein  stenosis  and  the  need  for  LVOT
obstruction  relief.  Pulmonary  vein  stenosis  is  a  marker  for
poor  outcome;  all  patients  without  pulmonary  vein  steno-
sis  survive  long  term.  Selamet  Tierney  et  al.  [35]  showed
that  supra-annular  MVR  was  associated  with  worse  sur-
vival  than  annular  MVR.  Supra-annular  placement  should
be  reserved  only  for  those  patients  in  whom  the  native
annulus  is  too  small  to  accept  a  commercially  available
valve.
Anticoagulants
The  administration  of  anticoagulants  (antivitamin  K
type)  after  MVR  is  essential.  Drawbacks  and  potential
complications  related  to  anticoagulants  should  be  con-
sidered,  but  literature  [26,32]  and  experience  in  the  use
of  anticoagulants  in  MV,  associated  with  rigorous  medical
observance  and  surveillance,  show  that  anticoagulants  in
the  paediatric  age  group  are  tolerated.
Pacemaker placement
Morphological  investigation  [38]  showed  that  the  AV  node
artery  runs  in  close  proximity  to  the  annulus  in  23%  of  cases.
Damage  to  the  AV  node  artery  may  play  a  role  in  the  devel-
opment  of  AV  block.  In  our  study  [32], four  children  (13%)
had  a  complete  AV  block  requiring  the  placement  of  a  per-
manent  pacemaker  during  the  ﬁrst  intervention.  Selamet
Tierney  et  al.  [35]  showed  that  patients  with  a  supra-annular
prosthesis  had  a  lower  risk  of  pacemaker  placement  in  the
early  post-MVR  period  than  those  with  an  annular  prosthesis,
but  remained  at  risk  when  the  prosthesis  was  subsequently
replaced  (Fig.  5)  [35].
Redo-MVR
We  performed  a  reintervention  for  MVR  in  10  patients
(37%);  among  them,  eight  patients  (27%)  have  been  reop-
erated  on  due  to  the  MV  becoming  restrictive.  All  these
patients  had  a  new  MV  at  least  two  sizes  larger  than  the
initial  valve.  No  mortality  was  observed  during  the  reope-
ration  of  patients.  We  showed  that  the  mitral  ring  may
expand  during  growth  even  if  there  is  a  prosthesis  all
around,  which  allowed  the  placement  of  a  bigger  prosthe-
sis  during  the  ulterior  operation.  Raghuveer  et  al.  have
conﬁrmed  this  point  [39]. However,  precautions  must  be
taken  not  to  use  oversized  prostheses  to  avoid  circumﬂex
compression.
t
i
et 1 month and 1 year, 78% at 5 years and 69% at 10 years after MVR
35].
In  a  multi-institutional  study  [30,39],  the  potential  uni-
ariate  predictors  of  second  MVR  were:  younger  age;  lower
eight;  increased  prosthetic  valve  size/body  weight  ratio;
hone’s  syndrome;  smaller  prosthesis;  and  prosthesis  other
han  St.  Jude’s.  In  our  study  [32], we  found  that  at  ﬁrst
ntervention,  weight  less  or  equal  to  7  kg  and  age  less  or
qual  to  1  year  were  associated  with  redo-MVR.  Our  low  level
f  redo-MVR  (76.7%  at  15  years)  compared  with  other  studies
29,35]  may  be  explained  by  our  strategy  of  waiting  as  long
s  possible  because  the  transmitral  gradient  increases  very
lowly  and  keeps  patients  asymptomatic  for  a  long  period  of
ime.
ight ventricular outﬂow tract
econstruction and/or pulmonary valve
eplacement
he  pulmonary  valve  is  the  most  common  valve  replaced
n  the  congenital  population.  Pulmonary  valve  replacement
PVR)  continues  to  be  a  ‘weak  link’  in  our  management  of
hildren  and  adults  with  congenital  heart  disease.  PVR  for  a
ewborn  with  truncus  arteriosus  is  vastly  different  from  PVR
or  an  adult  undergoing  reoperation  after  tetralogy  of  Fallot
epair  in  childhood.
A PH  was  the  PVR  option  of  choice  for  congenital  PVR  from
he  mid-1980s  to  2000.  Although  early  homograft  regurgita-
ion  in  non-Ross  AVRs  was  a  common  ﬁnding,  regurgitation
as  rarely  the  cause  of  valve  failure  or  an  indication  for
VR.  Obstruction  was  the  most  common  indication  for  PVR
fter  using  a  PH.  Most  large  series  report  the  need  for  rere-
lacement  of  a  PH  in  non-Ross  patients  within  5  to  7  years.
his,  however,  is  not  the  case  for  PHs  implanted  during  a
oss  AVR  because  the  PH  can  be  oversized  and  placed  in  a
rue  orthotopic  position.Evaluating  the  durability  of  the  PH  has  been  critical
n  determining  the  choice  of  prosthesis  for  PVR.  Forbess
t  al.  [40]  reviewed  185  consecutive  PH  implants  at  a  single
524  
Figure 6. Kaplan-Meier freedom from pulmonary homograft fail-
ure for Ross procedure and non-Ross procedure implants (A) in
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ularly  beyond  the  neonatal  period,  in  the  presence  of  aatients over 10 years of age and (B) for the three patient age groups
40].
nstitution  over  14  years.  Three  separate  age  groups  were
valuated.  Their  analysis  showed  that  smaller  homograft
ize,  younger  aged  patients  and  the  diagnosis  of  truncus
rteriosus  were  all  risk  factors  for  homograft  failure  in  a
nivariate  analysis.  Smaller  homograft  size  was  the  only
redictor  of  failure  in  multivariate  analysis.  Ross  procedure-
elated  implants  had  the  best  outcomes,  with  a  5-year  PH
urvival  of  94%  (Fig.  6A).  Non-Ross  PH  implants  in  children
lder  than  10  years  had  a  graft  survival  of  76%  (Fig.  6B).
The  largest  published  series  of  PVR  and  right  ventricle-
o-pulmonary  artery  conduits  came  from  Dearani  et  al.
41]  at  the  Mayo  Clinic,  who  described  late  follow-up
or  1095  patients  undergoing  right  ventricle-to-pulmonary
rtery  conduit  or  PVR  over  a  period  of  37  years.  During  this
eriod,  1270  RVOT  procedures  were  performed.
In  the  most  recent  decade,  mortality  was  3.7%.  Mean
ollow-up  for  the  entire  series  was  10.9  years,  with  a
r
v
vR.  Henaine  et  al.
aximum  of  29  years.  Three  types  of  conduits  were  used:
30  patients  received  porcine  valved  Dacron  conduits,  239
eceived  PHs  and  126  had  non-valved  conduits  implanted.
isk  factors  cited  for  conduit  failure  included  use  of  a  PH,
ounger  age  at  initial  operation  and  smaller  conduit  size.  An
dditional  RVOT  reconstruction  option  often  used  by  Husain
nd  colleagues  [8]  is  the  insertion  of  a  Gore-Tex  monocusp.
ransannular  incisions  were  required  in  40%  of  children  with
etralogy  of  Fallot  and  its  variants.  The  authors  found  that
se  of  the  Gore-Tex  monocusp  minimizes  early  and  midterm
alvular  regurgitation,  as  well  as  allowing  for  right  ven-
ricular  functional  recovery.  Freedom  from  reoperation  has
anged  from  87%  to  92%  at  10  years  based  on  subgroup  anal-
sis  of  RVOT  pathology.
The  Contegra  bovine  right  ventricular  pulmonary  artery
onduit  is  a  gluteraldehyde-preserved  bovine  jugular
enous-valved  conduit.  Size  availability  ranges  from  12
o  22  mm  in  diameter.  It  is  very  ‘user  friendly’,  there  is
o  requirement  for  postoperative  anticoagulation  and  the
alve  retains  better  competence  than  a  PH.  Initial  results
rom  Brown  et  al.  [42]  have  been  quite  promising;  their
ontegra  series  included  85  implants  in  patients  ranging
n  age  from  2  weeks  to  18  years.  There  have  been  two
arly  (3%)  and  four  late  (7%)  deaths,  with  none  being
onduit-related.  There  has  been  only  one  Contegra  conduit
xplantation  for  a  right  ventricular  pseudoaneurysm.  Seven
atients  have  required  reinterventions  to  relieve  stenosis
t  or  beyond  the  distal  conduit  anastomosis;  six  of  these
even  patients  required  balloon  dilatation  for  branch  level
tenosis  beyond  the  conduit  itself.  Thus  far,  they  have
ot  seen  any  evidence  of  conduit  shrinkage  or  signiﬁcant
ilation.
ancock porcine valved conduit
elli  et  al.  [43]  have  shown  the  long-term  outcome  of
14  patients  with  the  Hancock  porcine  valved  conduit.
edian  age  at  operation  was  62.5  months  (range,  1  week
o  50  years),  including  14  neonates  (6%)  The  higher  RVOT
ystolic  pressure  gradient  at  discharge  did  not  inﬂuence
onduit  longevity.  Conduit  reoperation  was  delayed  due  to
ercutaneous  balloon  dilatation  in  14  patients,  associated
ith  stenting  in  seven  patients.  Survival  with  freedom  from
onduit  reoperation  was  98%  at  1  year,  81%  at  5  years  and
2%  at  10  years.
During  the  study  period,  the  Hancock  conduit  was
xplanted  and  replaced  in  88  patients  at  a  median  delay
f  72.1  months  (range,  5  to  142  months)  (Fig.  7).
The  Hancock  valved  conduit  is  a  safe  and  reliable  alterna-
ive  to  homografts;  it  appears  to  be  appropriate  in  patients
ith  a  limited  pulmonary  vascular  bed  and  high  pulmonary
rtery  pressures.  Caution  is  required  in  neonates  because
f  the  rigidity  of  the  Dacron  housing.  Initial  results  with
econdary  percutaneous  procedures  are  encouraging.  Other
dvantages  of  the  Dacron  housing  are  that  it  allows  a  safer
pproach  and  easy  removal  during  conduit  reoperation  and
he  limitation  of  the  late  conduit  calciﬁcation  was  only  at
he  valvular  level.  The  authors  recommend  its  use  partic-estrictive  pulmonary  vascular  bed,  increased  pulmonary
ascular  resistance  or  both  and,  ﬁnally,  as  a  palliative  right
entricular  pulmonary  artery  conduit.
Valve  replacement  in  children  
Figure 7. Actuarial conduit longevity with the Hancock porcine
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cvalved conduit in pulmonary position. Actuarial conduit longevity
was 96% at 1 year, 64% at 5 years and 13% at 10 years [43].
Mechanical valves
MVs  and  valved  conduits  have  been  used  in  the  pulmonary
position  for  highly  selected  older  children  and  adults.
Chronic  anticoagulation  requirements  make  this  option  less
attractive.  Haas  et  al.  [44]  published  a  series  of  15  patients
over  a  5-year  period  who  received  a  MV  conduit  in  the
pulmonary  position.  All  patients  had  a  mean  of  3.0  ±  1.2
previous  operations.  All  patients  survived  the  operation.
At  follow-up  of  11  to  63  months,  all  but  two  patients  had
normal  right  ventricular  function,  with  a  mean  gradient  of
14  ±  9  mmHg  across  the  pulmonary  MV.  All  patients  were  on
anticoagulation  therapy  with  a  goal  international  normal-
ized  ratio  of  3.0  to  4.5.  Overall,  this  option  seems  feasible
for  highly  selected  patients,  especially  those  somewhat
older  patients  with  multiple  previous  operations,  patients
who  have  other  mechanical  heart  valves  and  patients  with
social  and  family  support  systems  to  monitor  and  administer
anticoagulation  therapy.
Bioprostheses
Surgical  relief  of  RVOT  obstruction  in  tetralogy  of  Fal-
lot  often  includes  a  transannular  incision  extending  from
the  muscular  infundibulum  to  the  main  pulmonary  artery.
Although  the  afterload  to  the  right  ventricle  is  reduced,
the  tradeoff  is  pulmonary  valvar  incompetence,  long-term
pulmonary  regurgitation  and  progressive  right  ventricle
dilation.  Right  ventricle  dilatation  is  associated  with  vulner-
ability  to  arrhythmia;  repaired  tetralogy  of  Fallot  patients
are  known  to  be  at  increased  long-term  risk  of  mortality.
A  potential  solution  to  this  problem  is  PVR,  with  the  goal
of  reversing  the  process  of  right  ventricle  dilation.  In  a
matched  comparison  with  a  similar  tetralogy  of  Fallot  group,
late  PVR  for  symptomatic  pulmonary  regurgitation/right
ventricle  dilation  did  not  reduce  the  incidence  of  ventricular
tachyarrhythmia  or  death  [45].
Our main  policy  is  to  perform  PVR  with  a  stented  bio-
prosthesis  (Mitroﬂow® or  Triﬂecta®)  with  pulmonary  branch
plasty  when  required  and  with  direct  closure  or  with
haemashield  patch  of  the  RVOT;  this  PVR  is  made  by  ster-
notomy  except  for  special  cases  [46], with  extracorporeal
circulation  and  without  cross-clamping  of  the  aorta.  The
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iming  of  the  intervention  should  be  as  late  as  possible.
hus,  between  2001  and  2011,  60  patients  in  our  institu-
ion  underwent  a  PVR  after  the  repair  of  tetralogy  of  Fallot
n  infancy.  The  median  age  at  PVR  was  29  years  (range,  12
o  66  years).  The  mean  time  between  initial  surgery  and  PVR
as  23.4  years.  No  death  occurred.  We  observed  an  improve-
ent  in  New  York  Heart  Association  functionality,  rhythm
egression  disturbances,  a  reduction  in  right  ventricular  vol-
mes  and  an  increase  in  left  ventricular  function.  For  the
oment,  without  any  evidence  for  survival  improvement,
e  keep  this  operation  for  symptomatic  patients  only.
ioprostheses are also used in our centre for
he repair of pulmonary agenesia in older
hildren
n  discussions  of  future  perspectives,  the  most  frequently
escribed  innovative  non-invasive  approach  is  percuta-
eous  PVR  with  the  Melody  Transcatheter  Pulmonary  Valve
Medtronic  Inc.,  Minneapolis,  MN,  USA).  This  technique  is
ctually  limited  to  a calciﬁed  pulmonary  prosthetic  conduit
ot  exceeding  22  mm  in  diameter  [47], however,  and  is  not
or  patients  with  repaired  tetralogy  of  Fallot  with  a  clearly
ilated  or  even  aneurysmal  pulmonary  artery  requiring  a
evice  of  larger  diameter.  Bioprosthesis  at  ﬁrst  PVR  supplies
 later  percutaneous  PVR  due  to  the  stented  bioprosthesis.
issue-engineered  pulmonary  valves  may  be  the  answer,  but
hat  answer  seems  far  away.
ithout prostheses
n  fact,  to  avoid  several  reinterventions,  some  authors
ecommend—as  in  truncus  arteriosus—RVOT  reconstruction
ith  a  partially  competent  monocuspid  valve  [48,49]  or  even
ithout  any  valve  (54),  but  long-term  data  are  still  lacking.
he  late  incidence  of  reintervention  for  RVOT  obstruction
r  pulmonary  valve  implantation  remains  to  be  determined
50].
ricuspid valve replacement
f  all  the  cardiac  valves,  the  tricuspid  is  the  least  com-
on  to  require  replacement,  making  up  less  than  2%  of  VRs
n  the  adult  population.  Tricuspid  valve  replacement  (TVR)
s  even  less  frequently  required  in  children.  Irreparable
bstein’s  tricuspid  valves  (TVs)  and  TV  endocarditis  are
he  two  most  frequent  indications  for  TVR  in  children.  In
he  largest  single-centre  report  of  TVR,  the  Mayo  Clinic
Rochester,  MN,  USA)  performed  more  than  323  TVRs  [51].
he  need  to  replace  the  TV  in  their  large  Ebstein’s  experi-
nce  was  greater  than  50%.  TVR  was  performed  when  TV
epair  was  not  feasible.  The  surprising  conclusion  of  this
entinel  report  was  that  older  children  requiring  TVR  with
bstein’s  anomaly  fared  better  than  children  requiring  TVR
or  other  disease  entities.  Bioprosthetic  valves  fared  bet-
er  in  the  TV  position  than  the  same  bioprosthesis  in  other
ardiac  positions.  Kiziltan  et  al.  [51]  reported  on  158  con-
ecutive  patients  requiring  TVR  for  Ebstein’s  anomaly  at  the
ayo  Clinic  over  a  25-year  period.  Follow-up  of  149  patients
ho  survived  30  days  ranged  up  to  17.8  years,  with  a  mean
f  4.5  years.  Survival  was  92.5%  at  both  10  and  15  years,  with
526  
Figure 8. Freedom from reoperation for tricuspid bioprosthesis
replacement for patients less or equal to 18 years of age in the
present series compared with freedom from reoperation for bio-
prosthesis replacement in all cardiac positions in patients less or
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[8] Husain SA, Brown JW. When reconstruction fails or is not
feasible: valve replacement options in the pediatric popula-qual to 18 years of age [8].
ine  late  deaths.  Freedom  from  bioprosthesis  replacement
as  97.5%  at  5  years  and  80.6%  at  both  10  and  15  years.  Sig-
iﬁcant  differences  were  noted  with  regard  to  freedom  from
eoperation  for  bioprosthesis  in  the  tricuspid  position  com-
ared  with  all  other  cardiac  positions  (Fig.  8)  [8].  In  addition,
reedom  from  reoperation  was  lower  for  bioprostheses  than
or  mechanical  prostheses  in  the  tricuspid  position.  Fur-
her  support  for  bioprostheses  in  the  tricuspid  position  has
een  provided  by  Guerra  et  al.  [52], who  reported  a  14-year
ollow-up  on  45  patients  at  a  single  institution.  Thirty-
ight  of  these  45  patients  also  had  other  valves  replaced
n  other  cardiac  positions  simultaneously  with  their  TVR.
orphological  examination  of  explanted  porcine  bioprosthe-
es  showed  that  those  implanted  in  the  tricuspid  position
ad  lower  degrees  of  calciﬁcation  and  less  severe  struc-
ural  changes  than  those  simultaneously  explanted  from  the
itral  position.  Overall,  actuarial  freedom  from  structural
eterioration  at  14  years  for  the  bioprosthesis  was  68%  in  the
ricuspid  position.
Shrestha  et  al.  [53], in  a  study  of  homograft  TVR,
ound  that  partial  replacement  of  the  TV  using  a  homo-
raft  provided  favourable  in-hospital  and  mid-  to  long-term
linical  outcomes  for  patients  with  a  variety  of  causes  and
ge  groups,  despite  a  slightly  complex  surgical  technique
ompared  with  prosthetic  VR.  This  procedure  might  be  use-
ul,  particularly  in  treating  active  bacterial  endocarditis  or
oung  patients,  in  centres  at  which  homograft  tissue  is  avail-
ble.
Finally,  Husain  and  Brown  [8]  recommend  that  the  valve
lacement  should  be  cephalad  to  the  coronary  sinus,  the
trioventricular  node  and  occasionally  the  right  coronary
rtery,  to  decrease  the  risk  that  the  prosthetic  sewing  ring  or
truts  will  compromise  these  structures;  great  care  should
e  taken  to  ensure  that  the  struts  of  the  bioprosthesis  strad-
le  the  area  of  the  membranous  septum  and  conduction
issue;  the  valve  should  be  seated  into  position  with  the
eart  beating  to  observe  rhythm  disturbances;  and  concomi-
ant  procedures,  such  as  a  right-sided  Maze  procedure,  can
nd  should  be  performed  at  the  time  of  TVR  if  indicated.R.  Henaine  et  al.
onclusions
R  in  children  is  a  complex  issue  because  of  initial  valve
nd  patient  size,  anatomy  and  growth  potential.  A  multi-
ude  of  opinions  and  surgical  experiences  exist.  Today,  the
alve  choices  that  seem  without  controversy  are  biopros-
hetic  VR  of  the  TV  and  Ross  AVR  for  the  aortic  valve.  On  the
ther  hand,  PVR  choice  remains  controversial.  Several  good
ptions  are  available  for  most  valvular  positions  when  VR  is
equired.  MVR  in  small  children  remains  the  most  problem-
tic.  The  Ross  procedure  produces  excellent  results  in  the
ortic  position  and  has  shown  promise  in  the  mitral  posi-
ion  in  selected  patients.  The  PA  offers  a  potential  durable
ption  in  both  of  these  positions.  Mechanical  VR  options  do
xist  for  children;  however,  chronic  anticoagulation  makes
Vs  less  desirable.  Future  advances  with  tissue-engineered
eart  valves  for  all  positions  and  new  anticoagulants  may
hange  the  landscape  for  VR  in  the  paediatric  population.
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